2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Whatever comes out of Congress on the “repeal and replace” of the Affordable Care Act (ACA or Obamacare) matters because it will affect the bottom line of the life sciences industry as well as all of its industry partners.
PsiOxus Therapeutics Ltd. agreed to grant Bristol-Myers Squibb Co. exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors.
Although virtually no one in the urban bubble where biopharmaceutical companies reside expected it to happen, Donald Trump won. So, now what?
Sanofi Pasteur in an email to urologists informed physicians and patients that it will stop manufacturing TheraCys, BCG Live, for bladder cancer recurrence.
The President-Elect Donald Trump Administration has a new website and has updated – sort of – Trump’s intended policies for healthcare and biopharma.
Before there are new therapies to set a firm apart, there is a far more fundamental need that competitiveness will ultimately hinge on: high-quality, diversified, annotated human biospecimens.
The ninth batch of presidential candidate Hillary Clinton’s emails released by WikiLeaks has some biopharma gossip that includes Clinton’s team discussing the FDA’s commissioner and it’s so-called “war on pharma.”
Boehringer Ingelheim and ViraTherapeutics will jointly develop a next-generation oncolytic virus therapy platform and investigate ViraTherapeutics’ lead candidate.
Biogen will test Anavex Life Sciences’ lead drug candidate, ANAVEX 2-73, in an oligodendrocyte precursor cell (OPC) differentiation assay.